News
AXSM
79.17
+3.19%
2.45
3 Best Stocks to Buy Now, 3/27/2024, According to Top Analysts 
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Axsome Therapeutics (AXSM) and Olink Holding (OLK)
TipRanks · 1d ago
Optimistic Buy Rating for Axsome Therapeutics: Diverse Portfolio and Market Potential Despite Challenges
TipRanks · 1d ago
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
NASDAQ · 1d ago
Axsome Therapeutics Price Target Maintained With a $150.00/Share by Truist Securities
Dow Jones · 2d ago
Axsome Therapeutics Is Maintained at Buy by Truist Securities
Dow Jones · 2d ago
Truist Securities Maintains Buy on Axsome Therapeutics, Maintains $150 Price Target
Benzinga · 2d ago
Truist Financial Remains a Buy on Axsome Therapeutics (AXSM)
TipRanks · 2d ago
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Keybanc boosted the price target for Worthington Steel, Inc. (NYSE:WS) on Monday. Morgan Stanley increased Seagate Technology Holdings plc's price target from $73 to $115. The Gap and The Gap Inc. Also had their price targets boosted by analysts.
Benzinga · 2d ago
Axsome Therapeutics Price Target Raised to $128.00/Share From $123.00 by RBC Capital
Dow Jones · 2d ago
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 2d ago
RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $128
Benzinga · 2d ago
Axsome Therapeutics Price Target Raised to $127.00/Share From $125.00 by Citigroup
Dow Jones · 2d ago
Axsome Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 2d ago
Citigroup Maintains Buy on Axsome Therapeutics, Raises Price Target to $127
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)
TipRanks · 2d ago
Axsome Therapeutics Price Target Raised to $190.00/Share From $180.00 by HC Wainwright & Co.
Dow Jones · 2d ago
Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
Buy Rating Affirmed for Axsome Therapeutics with Increased Target Price Following Strong AXS-12 Trial Results
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (AXSM) and set a price target of $190.00. The company is developing a drug to treat narcolepsy called AXS-12. The drug's probability of approval has been increased to 75%.
TipRanks · 2d ago
HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $190
Benzinga · 2d ago
More
Webull provides a variety of real-time AXSM stock news. You can receive the latest news about Axsome Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AXSM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.